Tenofovir Disoproxil Fumarate Hetero

Tenofovir Disoproxil Fumarate Hetero

tenofovir disoproxil fumarate




Hind Wing
Agencia Lei Va Hong
Concise Prescribing Info
Tenofovir disoproxil fumarate
In combination w/ other antiretroviral agents for treatment of HIV-1 infection in adults. Treatment of chronic HBV in adults.
Dosage/Direction for Use
300 mg once daily. Patient w/ CrCl ≥50 mL/min 300 mg every 24 hr; CrCl 30-49 mL/min 300 mg every 48 hr; CrCl 10-29 mL/min 300 mg every 72-96 hr. Hemodialysis patients 300 mg every 7 days or after a total of approx 12 hr of dialysis.
May be taken with or without food: Take consistently either always w/ or always w/o food.
Special Precautions
Prior to or when initiating treatment, test patients for HBV & HIV-1 infection. Prior to initiation & during treatment, on a clinically appropriate schedule, assess serum creatinine, estimated CrCl, urine glucose & urine protein in all patients. In patients w/ chronic kidney disease, also assess serum P. Severe acute exacerbations of hepatitis B upon discontinuation of anti-HBV therapy. Renal impairment, including cases of acute renal failure & Fanconi syndrome. Closely monitor renal function in all patients w/ CrCl <50 mL/min. Patients co-infected w/ HIV-1 & HBV. Immune reconstitution syndrome. Bone loss & mineralization defects. Lactic acidosis & severe hepatomegaly w/ steatosis. Avoid concurrent or recent use of a nephrotoxic agent. Should not be used in combination w/ other drugs containing tenofovir disoproxil fumarate, tenofovir alafenamide, or adefovir dipivoxil. Lactation. Elderly.
Adverse Reactions
Severe acute exacerbations of hepatitis B; new onset or worsening of renal impairment; immune reconstitution syndrome; bone loss & mineralization defects; lactic acidosis/severe hepatomegaly w/ steatosis.
Drug Interactions
Co-administration w/ drugs that are eliminated by active tubular secretion (eg, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides eg, gentamicin, & high-dose or multiple NSAIDs) may increase conc of tenofovir &/or the co-administered drug. Increased conc w/ drugs that decrease renal function; lopinavir/ritonavir, atazanavir/ritonavir, darunavir/ritonavir; sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir, ledipasvir/sofosbuvir. Increased conc of didanosine. Decreased conc of atazanavir.
MIMS Class
ATC Classification
J05AF07 - tenofovir disoproxil ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Tenofovir Disoproxil Fumarate Hetero tab 300 mg
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in